← back to search

Michael P. Bogenschutz

Arizona State University · US
Area of research
Epidemiology · Clinical Psychology
Research interest
Research interests include Substance Abuse Treatment and Outcomes, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior, and Opioid Use Disorder Treatment.
h-index
40
citations
8,031
works
162
NIH funding
primary concept
Medicine
email

Recent publications

Effects of cannabidiol in alcohol use disorder patients with and without co-occurring post-traumatic stress disorder: Tolerability but no evidence for efficacy in two randomized proof-of-concept trials.
2026cited by 1position: contributordoi
The science of psychedelic medicine.
2026cited by 0position: contributordoi
Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial
2026cited by 0position: contributordoi
A clinical research perspective on the regulation of medical and non-medical use of psychedelic drugs.
2025cited by 1position: contributordoi
Exploring the role of gender on treatment outcomes in older adults with alcohol use disorder.
2025cited by 1position: contributordoi
Relief craving severity moderates nonpharmacological treatment outcomes in treatment-seeking older adults with alcohol use disorder.
2025cited by 1position: contributordoi
Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.
2025cited by 0position: contributordoi
The Therapeutic Effects of Classic Psychedelics in Alcohol Use Disorder
Current Addiction Reports 2024cited by 2position: contributordoi
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
2024cited by 1position: contributordoi
Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer.
2024cited by 0position: contributordoi
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
Nature Medicine 2023cited by 375position: middledoi
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
2023cited by 225position: contributordoi
Improvement in quality of life among women and men aged 60 years and older following treatment for alcohol use disorder.
2023cited by 4position: contributordoi
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Nature Medicine 2021cited by 937position: middledoi
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
2021cited by 568position: contributordoi
Stability of Posttreatment Reductions in World Health Organization (WHO) Drinking Risk Levels and Posttreatment Functioning in Older Adults with DSM-5 Alcohol Use Disorder: Secondary Data Analysis of the Elderly Study.
2021cited by 5position: contributordoi
Evaluation of adding the community reinforcement approach to motivational enhancement therapy for adults aged 60 years and older with DSM-5 alcohol use disorder: a randomized controlled trial.
2020cited by 28position: contributordoi
Gabapentin Enacarbil Extended‐Release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial
Alcoholism Clinical and Experimental Research 2020cited by 22position: middledoi
Gabapentin Enacarbil Extended-Release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial.
2020cited by 15position: contributordoi
Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder.
2020cited by 9position: contributordoi
The Alcohol Dependence Scale and DSM-5 alcohol use disorder: Severity ratings correspond insufficiently in older patients.
2020cited by 8position: contributordoi
Stroop-related cerebellar and temporal activation is correlated with negative affect and alcohol use disorder severity.
2020cited by 7position: contributordoi
Implementation of strength-based case management for opioid-dependent patients presenting in medical emergency departments: rationale and study design of a randomized trial.
2020cited by 4position: contributordoi
Impact of comorbid mental disorders on outcomes of brief outpatient treatment for DSM-5 alcohol use disorder in older adults.
2020cited by 1position: contributordoi
Benefit-cost analysis of SBIRT interventions for substance using patients in emergency departments
Journal of Substance Abuse Treatment 2017cited by 26position: lastdoi
Classic hallucinogens in the treatment of addictions
Progress in Neuro-Psychopharmacology and Biological Psychiatry 2015cited by 224position: firstdoi
Outpatient treatment of alcohol use disorders among subjects 60+ years: design of a randomized clinical trial conducted in three countries (Elderly Study)
BMC Psychiatry 2015cited by 43position: middledoi
Brief Intervention for Patients With Problematic Drug Use Presenting in Emergency Departments
JAMA Internal Medicine 2014cited by 118position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

· 12 papers (2023–2026)Kjeld Andersen · University of Southern Denmark7 papers (2020–2025)Jennifer Mitchell · Utah Valley University5 papers (2021–2024)Marcela Ot’alora G · 3 papers (2021–2024)Silke Behrendt · University of Southern Denmark3 papers (2020–2025) · 3 papers (2021–2024)Anette Søgaard Nielsen · University of Southern Denmark3 papers (2020–2025)Alyssa A. Forcehimes · University of New Mexico3 papers (2014–2017)Jeppe Sig Juelsgaard Tryggedsson · SDU2 papers (2023–2025)Michael Mithoefer · Publons2 papers (2023–2024)B. A. Pagni · New York University2 papers (2024–2026)Randi Bilberg · SDU2 papers (2023–2025)Cole J. Marta · Multidisciplinary Association for Psychedelic Studies2 papers (2021–2023)Yevgeniy Gelfand · Multidisciplinary Association for Psychedelic Studies2 papers (2021–2023)Revital Amiaz · Alzheimer's Association of Israel2 papers (2021–2023)Scott Hamilton · Employee Benefit Research Institute2 papers (2021–2023)Sylvestre Quevedo · University of California, San Francisco2 papers (2021–2023)Ray Worthy · Multidisciplinary Association for Psychedelic Studies2 papers (2021–2023)Cameron Crandall · University of New Mexico2 papers (2014–2017)Randall Brown · Teva Pharmaceuticals (United States)2 papers (2021–2023)